Table 2.
Factors Associated with URI and LRI in HM Patients with Influenza (n=190)
| Number of patients (%) |
Entire cohort | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Characteristic | URI (n=110) |
LRI (n=80) |
Unadjusted OR (95% CI) |
P | Adjusted OR (95% CI) |
P |
| Age | 49 (1–80)a | 50 (8–88)a | 1.12 (0.97–1.29)b | 0.119 | 1.20 (0.95–1.52)b | 0.120 |
| Sex | 0.654 | 0.450 | ||||
| Female | 42 (38) | 28 (35) | 1.00 | 1.00 | ||
| Male | 68 (62) | 52 (65) | 1.15 (0.63–2.09) | 1.39 (0.59–3.27) | ||
| Influenza season | 0.188 | 0.573 | ||||
| H1N1 (April 2009–May 2010) | 30 (27) | 29 (36) | 1.00 | 1.00 | ||
| Post-H1N1 (November 2010–February 2014) | 80 (73) | 51 (64) | 0.66 (0.35–1.26) | 0.76 (0.29–1.99) | ||
| Type of malignancy | 0.545 | 0.016 | ||||
| Lymphoma/myeloma | 53 (48) | 35 (44) | 1.00 | 1.00 | ||
| Leukemia | 57 (52) | 45 (56) | 1.20 (0.67–2.13) | 3.09 (1.23–7.70) | ||
| Cancer status | 0.090 | 0.305 | ||||
| Remission | 31 (28) | 14 (18) | 1.00 | 1.00 | ||
| Active/refractory | 79 (72) | 66 (82) | 1.85 (0.91–3.77) | 0.61 (0.24–1.56) | ||
| Corticosteroid use | 0.002 | 0.043 | ||||
| No | 90 (82) | 49 (61) | 1.00 | 1.00 | ||
| Yes | 20 (18) | 31 (39) | 2.85 (1.47–5.51) | 2.71 (1.03–7.15) | ||
| BMI | 0.135 | 0.159 | ||||
| Normal/underweight | 39 (35) | 37 (46) | 1.00 | 1.00 | ||
| Overweight/obese | 71 (65) | 43 (54) | 0.64 (0.35–1.15) | 0.53 (0.22–1.28) | ||
| Neutropenia | 0.004 | 0.287 | ||||
| No | 96 (87) | 56 (70) | 1.00 | 1.00 | ||
| Yes | 14 (13) | 24 (30) | 2.94 (1.41–6.14) | 1.87 (0.59–5.89) | ||
| Lymphocytopenia | 0.012 | 0.533 | ||||
| No | 95 (86) | 57 (71) | 1.00 | 1.00 | ||
| Yes | 15 (14) | 23 (29) | 2.56 (1.23–5.29) | 1.44 (0.46–4.53) | ||
| Decreased albumin level | <0.001 | 0.003 | ||||
| No | 89 (81) | 26 (33) | 1.00 | 1.00 | ||
| Yes | 21 (19) | 54 (67) | 8.80 (4.52–17.15) | 3.78 (1.55–9.20) | ||
| Elevated creatinine level | 0.793 | 0.742 | ||||
| No | 91 (83) | 65 (81) | 1.00 | 1.00 | ||
| Yes | 19 (17) | 15 (19) | 1.11 (0.52–2.34) | 1.20 (0.40–3.59) | ||
| Hypoxia at diagnosisc | <0.001 | <0.001 | ||||
| No | 100 (91) | 39 (49) | 1.00 | 1.00 | ||
| Yes | 9 (9) | 40 (50) | 11.40 (5.06–25.68) | 14.98 (3.30–67.90) | ||
| Antiviral therapy within 24 hours of onset of symptoms | 0.588 | 0.591 | ||||
| No | 99 (90) | 70 (88) | 1.00 | 1.00 | ||
| Yes | 11 (10) | 10 (12) | 1.29 (0.52–3.19) | 1.46 (0.36–5.88) | ||
| Respiratory co-infection | <0.001 | 0.006 | ||||
| No | 104 (95) | 58 (73) | 1.00 | 1.00 | ||
| Yes | 6 (5) | 22 (27) | 6.57 (2.52–17.14) | 5.87 (1.65–20.86) | ||
| Center | <0.001 | 0.649 | ||||
| 1 | 91 (83) | 44 (55) | 1.00 | 1.00 | ||
| 2 | 19 (17) | 36 (45) | 3.92 (2.02–7.59) | 0.72 (0.17–3.01) | ||
a
Median (range),
b
Age interval of 10 years,
c
data available for 188 patients only